Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) had its price objective boosted by research analysts at Mizuho from $13.00 to $16.00 in a research report issued on Monday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 5.26% from the company’s current price.

A number of other brokerages have also weighed in on SCMP. Northland Securities started coverage on shares of Sucampo Pharmaceuticals in a report on Wednesday, September 7th. They issued an “outperform” rating and a $15.00 price objective for the company. Vetr upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a report on Thursday, September 29th. Jefferies Group decreased their price objective on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a report on Thursday, August 4th. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Finally, Maxim Group decreased their price objective on shares of Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating for the company in a report on Monday, August 1st. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $17.11.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 15.20 on Monday. The stock has a 50 day moving average price of $12.64 and a 200-day moving average price of $11.75. Sucampo Pharmaceuticals has a 12-month low of $9.59 and a 12-month high of $18.75. The company has a market capitalization of $650.74 million, a price-to-earnings ratio of 51.35 and a beta of 1.62.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company earned $57.90 million during the quarter, compared to analyst estimates of $51.30 million. During the same period in the previous year, the business earned $0.16 EPS. The firm’s revenue for the quarter was up 73.4% on a year-over-year basis. Equities analysts predict that Sucampo Pharmaceuticals will post $1.15 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of SCMP. Citadel Advisors LLC raised its stake in Sucampo Pharmaceuticals by 177.2% in the third quarter. Citadel Advisors LLC now owns 34,091 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 21,791 shares during the period. Piermont Capital Management Inc. raised its stake in Sucampo Pharmaceuticals by 9.4% in the third quarter. Piermont Capital Management Inc. now owns 67,269 shares of the biopharmaceutical company’s stock valued at $828,000 after buying an additional 5,770 shares during the period. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals during the third quarter valued at approximately $142,000. Skandinaviska Enskilda Banken AB publ raised its stake in Sucampo Pharmaceuticals by 7.5% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 395,400 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 27,500 shares during the period. Finally, Northern Trust Corp raised its stake in Sucampo Pharmaceuticals by 5.3% in the third quarter. Northern Trust Corp now owns 307,766 shares of the biopharmaceutical company’s stock valued at $3,788,000 after buying an additional 15,374 shares during the period. Hedge funds and other institutional investors own 41.14% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.